Granted Patent B2

US 12,390,451 · App. 17/690,380 · Granted Aug 19, 2025

Inventors: Edward F. Attiyeh (Villanova, PA); Kurtis E. Bachman (Chester Springs, PA); Gerald C. Chu (Philadelphia, PA); Tatiana Koudriakova (Poway, CA); David C. Polidori (Rancho Santa Fe, CA); Gary V. Borzillo (Upper Gwynedd, PA)

Assignee: Janssen Pharmaceutica NV

A61K31/437A61K45/06A61P1/00A61P35/00C12Q1/6886C12Q2600/106C12Q2600/156C12Q2600/158

Abstract

Claims (12)

1. A method of treating familial adenomatous polyposis in a subject in need thereof comprising administering to the subject a composition comprising about 75 mg of compound of Formula I or a pharmaceutically acceptable salt thereof twice daily

2. A method of treating stomacho-intestinal system cancer in a subject in need thereof comprising administering to the subject a composition comprising about 75 mg of compound of Formula I or a pharmaceutically acceptable salt thereof twice daily

3. A method of treating colorectal cancer in a subject in need thereof comprising administering to the subject a composition comprising about 75 mg of compound of Formula I or a pharmaceutically acceptable salt twice daily

4. The method of claim 1 , wherein the subject has previously received a therapy or is currently receiving a therapy.

5. The method of claim 4 , wherein the therapy is selected from surgery, radiation therapy, chemotherapy, NSAIDs, Cox-2 inhibitors, EGFR inhibitors, VEGF inhibitors, and checkpoint inhibitors.

6. The method of claim 1 , further comprising administering a second active agent in combination with the compound of Formula I, wherein the second active agent is selected from NSAIDs, Cox-2 inhibitors, cetuximab, panitumumab, bevacizumab, Ziv-aflibercept, regorafenib, ramucirumab, ipilimumab, nivolumab, and pembrolizumab.

7. The method of claim 2 , wherein the subject has previously received a therapy or is currently receiving a therapy.

8. The method of claim 7 , wherein the therapy is selected from surgery, radiation therapy, chemotherapy, NSAIDs, Cox-2 inhibitors, EGFR inhibitors, VEGF inhibitors, and checkpoint inhibitors.

9. The method of claim 2 , further comprising administering a second active agent in combination with the compound of Formula I, wherein the second active agent is selected from NSAIDs, Cox-2 inhibitors, cetuximab, panitumumab, bevacizumab, Ziv-aflibercept, regorafenib, ramucirumab, ipilimumab, nivolumab, and pembrolizumab.

10. The method of claim 3 , wherein the subject has previously received a therapy or is currently receiving a therapy.

11. The method of claim 10 , wherein the therapy is selected from surgery, radiation therapy, chemotherapy, NSAIDs, Cox-2 inhibitors, EGFR inhibitors, VEGF inhibitors, and checkpoint inhibitors.

12. The method of claim 3 , further comprising administering a second active agent in combination with the compound of Formula I, wherein the second active agent is selected from NSAIDs, Cox-2 inhibitors, cetuximab, panitumumab, bevacizumab, Ziv-aflibercept, regorafenib, ramucirumab, ipilimumab, nivolumab, and pembrolizumab.

Assignments (2)

Continuity (4)

References Cited (216)